Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005062957 - COMPOSITIONS AND METHODS FOR COMBINED THERAPY OF DISEASE

Publication Number WO/2005/062957
Publication Date 14.07.2005
International Application No. PCT/US2004/043454
International Filing Date 23.12.2004
IPC
C07K 14/515 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
515Angiogenic factor; Angiogenin
C07H 21/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
04with deoxyribosyl as saccharide radical
A61K 48/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
CPC
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 48/005
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
005characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
A61P 13/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
13Drugs for disorders of the urinary system
08of the prostate
A61P 17/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
06Antipsoriatics
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 27/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
27Drugs for disorders of the senses
02Ophthalmic agents
Applicants
  • THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US]/[US] (AllExceptUS)
  • REICH, Samuel, J. [US]/[US] (UsOnly)
  • TOLENTINO, Michael, J. [US]/[US] (UsOnly)
Inventors
  • REICH, Samuel, J.
  • TOLENTINO, Michael, J.
Agents
  • FRANK, George, A.
Priority Data
60/532,09923.12.2003US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS FOR COMBINED THERAPY OF DISEASE
(FR) COMPOSITIONS ET PROCEDES POUR LA THERAPIE COMBINEE DE MALADIE
Abstract
(EN) A desired physiological state can be induced by altering the amount of gene products in target cells of a subject. The target cells are treated with at least one compound designed to reduce expression of at least one first gene by RNAi, and with at least one compound designed to increase expression from at least one second gene. The reduced expression of the first gene and the increased expression from the second gene in the target cells induces the desired physiological state in the subject. By altering target cell gene expression in this way, conditions such as angiogenesis or tumor growth and metastasis can be inhibited.
(FR) La présente invention a trait à un procédé permettant d'induire une condition physiologique souhaitée par la modification de produits génétiques dans des cellules cibles d'un sujet. Les cellules cibles sont traitées avec au moins un composé destiné à réduire l'expression d'au moins un premier gène par l'ARNi, et avec au moins un composé destiné à accroître l'expression à partir d'au moins un deuxième gène. L'expression réduite du premier gène et l'expression accrue à partir du deuxième gène dans les cellules cibles induit la condition physiologique souhaitée chez le sujet. Grâce à la modification de l'expression génétique des cellules cibles de cette manière, des conditions telles que l'angiogenèse ou la croissance et métastase tumorale peuvent être inhibées.
Latest bibliographic data on file with the International Bureau